Imperial researchers are on the hunt for biological markers which could ultimately help to treat patients with peanut allergy.
A team, led by Dr Mohamed Shamji at the National Heart & Lung Institute at Imperial, will analyse blood samples from patients with peanut allergy to search for common biomarkers.
Dr Shamji and team will work closely with Allergy Therapeutics, with the data from patients laying the groundwork for future trials of a peanut allergy vaccine, based on an allergen particle from peanuts.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.